5-Fluorouracil: identification of novel downstream mediators of tumour response

John Boyer; Pamela J Maxwell; Daniel B Longley; Patrick G Johnston

5-Fluorouracil: identification of novel downstream mediators of tumour response

John Boyer, Pamela J Maxwell, Daniel B Longley, Patrick G Johnston

Research output: Contribution to journal › Article › peer-review

Abstract

5-Fluorouracil (5-FU) is routinely used in the treatment of gastrointestinal, breast and head and neck cancers. A major limitation to the use of this drug is acquired or inherent resistance.

Original language	English
Pages (from-to)	417-23
Number of pages	7
Journal	Anticancer Research
Volume	24
Issue number	2A
Publication status	Published - 2004

UN SDGs

This output contributes to the following Sustainable Development Goal(s)

Fingerprint Dive into the research topics of '5-Fluorouracil: identification of novel downstream mediators of tumour response'. Together they form a unique fingerprint.

Cite this

@article{c7bc6471280d4a9eb05d1f4aed8d1b38,

title = "5-Fluorouracil: identification of novel downstream mediators of tumour response",

abstract = "5-Fluorouracil (5-FU) is routinely used in the treatment of gastrointestinal, breast and head and neck cancers. A major limitation to the use of this drug is acquired or inherent resistance.",

author = "John Boyer and Maxwell, {Pamela J} and Longley, {Daniel B} and Johnston, {Patrick G}",

year = "2004",

language = "English",

volume = "24",

pages = "417--23",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "2A",

}

TY - JOUR

T1 - 5-Fluorouracil

T2 - identification of novel downstream mediators of tumour response

AU - Boyer, John

AU - Maxwell, Pamela J

AU - Longley, Daniel B

AU - Johnston, Patrick G

PY - 2004

Y1 - 2004

N2 - 5-Fluorouracil (5-FU) is routinely used in the treatment of gastrointestinal, breast and head and neck cancers. A major limitation to the use of this drug is acquired or inherent resistance.

AB - 5-Fluorouracil (5-FU) is routinely used in the treatment of gastrointestinal, breast and head and neck cancers. A major limitation to the use of this drug is acquired or inherent resistance.

M3 - Article

C2 - 15152939

VL - 24

SP - 417

EP - 423

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 2A

ER -